Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.

CONCLUSIONS: The association of age with toxicity and of mHSPC stage with response resulted in significantly fewer grade 3 to 5 adverse events but higher response rates for upfront docetaxel in mHSPC compared with docetaxel in the later mCRPC stage.
PMID: 31377168 [PubMed - as supplied by publisher]

Source: Urologic Oncology - July 30, 2019 Category: Urology & Nephrology Authors: Mager R, Savko O, Böhm K, Thomas A, Dotzauer R, Borgmann H, Jäger W, Thomas C, Haferkamp A, Höfner T, Tsaur I Tags: Urol Oncol Source Type: research